Hereditary Angioedema Market

Market Overview:

The 7 major Hereditary Angioedema markets reached a value of USD 1.9 Billion in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 3.6 Billion by 2035, exhibiting a growth rate (CAGR) of 5.9% during 2025-2035.

The Hereditary Angioedema market has been comprehensively analyzed in IMARC's new report titled "Hereditary Angioedema Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035". Hereditary Angioedema Market is currently witnessing strong growth driven by advances in identifying mechanisms of angioedema and developing modern safe and effective drugs to treat the disease. Furthermore, increasing global accessibility of advanced diagnostic tools and medications and improving drug development times have also created a positive impact on the market. Hereditary angioedema, or HAE, refers to a rare genetic disorder that is caused by dysfunctional or lack of C1-inhibitor protein. This condition is inherited in an autosomal dominant pattern, implying one copy of the altered gene in each cell is enough to cause the indication. It is characterized by recurrent episodes of rapid, severe, subcutaneous, and submucosal swelling of the face, hands, airways, intestinal tract, trachea, larynx, or tongue without the appearance of urticarial lesions. Hereditary angioedema affects the blood vessels and leads to extreme pain, nausea, vomiting, fatigue, diarrhea, muscle ache, tingling, headache, abdominal pain, hoarseness, and mood swings. It also results in fluid leakage through the walls of blood vessels into body tissues. Hereditary angioedema (HAE) affects around 1 in 50,000 of the population and does not show ethnic variation in frequency. Similar to other rare conditions, there is often a delay to diagnosis the indication, resulting in patients not receiving appropriate treatment at the right time.

IMARC Group's new report provides an exhaustive analysis of the Hereditary Angioedema market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for Hereditary Angioedema and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Hereditary Angioedema market in any manner.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, Current and Future Epidemiology Scenario
• Historical, Current and Future Performance of the Hereditary Angioedema Market
• Historical, Current and Future Performance of Various Therapeutic Categories in the Hereditary Angioedema Market
• Sales of Various Drugs Across the Hereditary Angioedema Market
• Reimbursement Scenario in the Hereditary Angioedema Market

Competitive Landscape:

This report also provides a detailed analysis of the current Hereditary Angioedema marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report

Key Questions Answered in this Report:

Market Insights

• How has the Hereditary Angioedema market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to be in 2035?
• What was the country-wise size of the Hereditary Angioedema market across the seven major markets in 2024 and how will it look like in 2035?
• What is the growth rate of the Hereditary Angioedema market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the Hereditary Angioedema market?

Epidemiology Insights

• What is the number of prevalent cases (2019-2035) of Hereditary Angioedema across the seven major markets?
• What is the number of prevalent cases (2019-2035) of Hereditary Angioedema by age across the seven major markets?
• What is the number of prevalent cases (2019-2035) of Hereditary Angioedema by gender across the seven major markets?
• What is the number of prevalent cases (2019-2035) of Hereditary Angioedema by type across the seven major markets?
• How many patients are diagnosed (2019-2035) with Hereditary Angioedema across the seven major markets?
• What is the size of the Hereditary Angioedema patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend Hereditary Angioedema of?
• What will be the growth rate of patients across the seven major markets?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for Hereditary Angioedema drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Hereditary Angioedema market?
• What are the key regulatory events related to the Hereditary Angioedema market?
• What is the structure of clinical trial landscape by status related to the Hereditary Angioedema market?
• What is the structure of clinical trial landscape by phase related to the Hereditary Angioedema market?
• What is the structure of clinical trial landscape by route of administration related to the Hereditary Angioedema market?